

A trading division of Pharmacy Retailing (NZ) Limited

ProPharma

PO Box 62027, Sylvia Park, Auckland 1644 Phone 09 570 1080 Fax 09 915 9581 www.propharma.co.nz

5 January 2024

Dear Pharmacist,

Re: Shelf-life extension of Paxlovid (nirmatrelvir 150 mg/ritonavir 100 mg), film coated tablets, batch number GJ2963

There has been a shelf-life extension for Paxlovid (nirmatrelvir 150 mg/ritonavir 100 mg), film coated tablets, batch number GJ2963. The shelf life for this batch has been extended until March 2024 as long as the approved storage conditions have been maintained. The storage conditions of store below 25 degrees Celsius remains unchanged.

This notice is being issued after consultation between Medsafe and Pharmac.

Original Expiry date (Printed date on box, blister packaging and carton)	Updated Expiry date	Batch Number
12/2023	03/2024	GJ2963

Information provided to Pharmac by Pfizer includes the following suggestions for Pharmacists:

- 1. Please update your dispensary team on the Paxlovid shelf-life extension and ensure they read a copy of this letter.
- 2. Inform your dispensary team and other team members who may interact with patients and whanau regarding medication.
- 3. Please add a manual pop-up to your dispensary software to remind your team about the change.
- 4. It is important that you discuss the shelf-life extension with your patients.
- 5. When dispensing Paxlovid, it is suggested that you put a note in the dispensing basket to have a conversation with the patient.
- 6. If you still have available blank stickers/labels previously provided for short dated Paxlovid, then you can use these.
- 7. Patients **must be** advised to disregard the printed expiry date on the blister packs and advised of the updated expiry date.



Leaders in pharmacy supply, finance, valuations and support Connecting pharmacy buyers and sellers



PLEASE REVIEW THE CURRENT NEW ZEALAND DATA SHEET BEFORE PRESCRIBING OR DISPENSING.

The New Zealand Data Sheet and Consumer Medicine Information can be found at <u>https://www.medsafe.govt.nz</u>.

Adverse Event Reporting

Healthcare professionals are asked to report any suspected adverse events at https://nzphvc.otago.ac.nz/reporting/. Alternatively, any adverse events which are experienced with PAXLOVID can be reported to Pfizer on 0800 736 363 or by email to <u>AUS.AEReporting@pfizer.com</u>.

Medical Enquiries

Please direct any medical enquiries to Medical Information via www.pfizermedicalinformation.co.nz or 0800 736 363

Please can you ensure a copy of this letter remains with this specific batch of Paxlovid in your dispensary.

Thanking you in advance for your assistance.

Yours sincerely,

Alanurik

ALISON VAN WYK Executive General Manager ProPharma NZ